Plasma cell proliferation in monoclonal gammopathy: Relations with other biologic variables—Diagnostic and prognostic significance
- 1 January 1995
- journal article
- Published by Elsevier in The American Journal of Medicine
- Vol. 98 (1) , 60-66
- https://doi.org/10.1016/s0002-9343(99)80081-3
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging systemBlood, 1992
- Interleukin-6 is a prognostic factor in multiple myeloma [letter] [see comments]Blood, 1991
- Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias.Journal of Clinical Investigation, 1989
- Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6Blood, 1989
- Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomasNature, 1988
- Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapyBritish Journal of Haematology, 1984
- Beta-2-microglobulin in myeloma: optimal use for staging, prognosis, and treatment--a prospective study of 160 patientsBlood, 1984
- Clinical, morphological, and cell kinetic differences among multiple myeloma, monoclonal gammopathy of undetermined significance, and smoldering multiple myelomaBlood, 1983
- Ploidy and proliferative characteristics in monoclonal gammopathiesBlood, 1982
- Pretreatment tumor mass, cell kinetics, and prognosis in multiple myelomaBlood, 1980